Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India
Betsy Goodfellow | September 14, 2023 | News story | Sales and Marketing | License Agreement, Neurology, Pharmazz, Sun Pharma, Tyvalzi, sovateltide
Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a license agreement with Pharmazz in order to commercialise a first-in-class innovative drug, Tyvalzi (sovateltide) in India.
The drug was developed by Pharmazz and is indicated for the treatment of cerebral ischemic stroke.
Under the terms of this agreement, Sun Pharma has been granted rights for marketing the drug in India under the brand name Tyvalzi. Pharmazz will also be entitled to both upfront and milestone payments, including royalties.
Kirti Ganorkar, CEO of the India Business at Sun Pharma, commented: “The phase 3 clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke. Tyvalzi is a first-in-class innovative drug which can help improve the quality of life of stroke patients. The drug can be administered within 24 hours for the treatment of ischemic stroke. The current treatment options provide a narrow time window of 4-5 hours limiting its use in most patients.”
Dr Professor Anil Gulati, MD PhD, inventor, CEO and chairman of the board of directors at Pharmazz, added: “It is a significant step for Pharmazz to partner with Sun Pharma, the largest pharmaceutical company in India. For patients with cerebral ischemic stroke, I believe Sun Pharma is the best partner for Pharmazz to market Tyvalzi (Sovateltide), an innovative, first-in-class novel treatment for cerebral ischemic stroke, in India.”
Betsy Goodfellow
Related Content
GSK and CureVac to restructure collaboration into licensing agreement
GSK and CureVac have announced that they have restructured their existing collaboration into a license …
ERS Genomics and IRBM sign license agreement for CRISPR/Cas9
ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license …
Provectus Biopharmaceuticals announces license agreement with University of Miami
Provectus Biopharmaceuticals has announced that it has entered into an exclusive worldwide license agreement with …
